Meeting
2018 Gastrointestinal Cancers Symposium
Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion.
Authors
Garry Alan Weems
Lycera Corp., Plymouth Meeting, PA
Garry Alan Weems , Xiao Hu , Xikui Liu , Hongxiu Li , Madhumita Bogdan , Yilin Gao , Brian Fox , H. Jeffrey Wilkins , Laura Carter
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 67)
DOI
10.1200/JCO.2018.36.4_suppl.67
Abstract #
67
Poster Bd #
F19
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion.
First Author: Xiao Hu
Poster
2022 ASCO Annual Meeting
Characterization of NY-ESO-1 gene expression in gastric cancer (GC).
First Author: Annika Lenz
Poster
2021 ASCO Annual Meeting
High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.
First Author: Andreas Seeber
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation.
First Author: Laura Carter